Gilead Sciences to acquire Kite Pharma for $11.9bn
29-08-2017
CIPhotos / iStockphoto.com
Pfizer has revealed its plan to take a 25% stake in Allogene Therapeutics to further develop Pfizer’s allogeneic chimeric antigen receptor T cell (CAR T) therapy.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Allogene Therapeutics, cancer, oncology, Kite Pharma, CAR T therapy, collaboration